免疫组织化学法与荧光原位杂交法在乳腺癌HER2蛋白表达和基因扩增检测中的应用效果分析  

Analysis of the Application Effects of Immunohistochemistry and Fluorescence In Situ Hybridization in Detecting HER2 Protein Expression and Gene Amplification in Breast Cancer

作　　者：薛江波[1] 杨迪[1] 杨文君[1] 赵亚蒙 严君凯 XUE Jiangbo;YANG Di;YANG Wenjun;ZHAO Yameng;YAN Junkai(Pathology Department,Sanmenxia Central Hospital,Sanmenxia Henan 472000,China)

机构地区：[1]三门峡市中心医院病理科,河南三门峡472000

出　　处：《临床研究》2025年第3期132-135,共4页Clinical Research

摘　　要：目的探究乳腺癌人表皮生长因子受体2(HER2)的临床检验中,通过免疫组织化学法分析其蛋白表达,同时通过荧光原位杂交法分析其基因扩增情况的价值。方法选取三门峡市中心医院2022年1月至2024年4月收入的96例乳腺癌患者,对其均开展两项临床检验方案(免疫组织化学法+荧光原位杂交法),分析其检测结果与一致性情况。结果免疫组织化学法检测结果显示,96例研究样本中,HER2(3+)34例(35.42%),HER2(2+)59例(61.46%),HER2(1+)3例(3.12%),在阳性率情况方面,具体数据为35.42%。荧光原位杂交法检测结果显示,HER2扩增例数共计44例(45.83%),未扩增例数共计52(54.17%),同时在部分研究对象的检测结果中显示HER2和17号染色体着丝粒信号共同有扩增现象。3例免疫组织化学法检测阴性样本,荧光原位杂交法的检测结果均呈现出未扩增的情况,两者间的符合率:100.00%;59例经过免疫组织化学法进行检测,且检查结果显示为HER2(2+)的样本中,荧光原位杂交法的检测结果呈现出扩增的情况10例,两者间的符合率:16.95%;34例免疫组织化学法检测HER2阳性(3+)样本,荧光原位杂交法的检测结果均呈现出扩增的情况,两者间的符合率:100.00%;两种检测方案一致性较佳,差异具有统计学意义(Kappa=0.77,P<0.05)。结论乳腺癌HER2的临床检验中,通过免疫组织化学法分析其蛋白表达,同时通过荧光原位杂交法分析其基因扩增情况的价值较为理想,一致性较优,可进行临床应用。Objective To explore the clinical utility of analyzing Human epidermal receptor 2(HER2)protein expression in breast cancer using immunohistochemistry and assessing gene amplification using fluorescence in situ hybridization.Methods A total of 96 breast cancer patients admitted to Sanmenxia Central Hospital from January 2022 to April 2024 were selected.Both clinical testing methods(immunohistochemistry+fluorescence in situ hybridization)were employed,and the results and their consistency were analyzed.Results The results of immunohistochemistry showed that out of the 96 samples,34 cases were HER2(3+)(35.42%),59 cases were HER2(2+)(61.46%),and 3 cases were HER2(1+)(3.12%),resulting in a positive rate of 35.42%.The fluorescence in situ hybridization results indicated that there were a total of 44 cases(45.83%)with HER2 amplification and 52 cases(54.17%)without amplification.Additionally,some results showed concurrent amplification of HER2 and chromosome 17 centromere signals.Among the 3 immunohistochemistry-negative samples,the fluorescence in situ hybridization results all indicated no amplification,achieving a consistency rate of 100.00%.For the 59 samples,which were HER2(2+)by immunohistochemistry,10 cases showed amplification by fluorescence in situ hybridization,giving a consistency rate of 16.95%.For the 34 HER2(3+)positive samples,the fluorescence in situ hybridization results all indicated amplification,achieving a consistency rate of 100.00%.The consistency between the two testing methods was good,with a statistically significant difference(Kappa=0.77,P<0.05).Conclusion The clinical testing of HER2 in breast cancer through immunohistochemistry for protein expression and fluorescence in situ hybridization for gene amplification is of ideal value,showing good consistency and is suitable for clinical application.

关 键 词：乳腺癌 免疫组织化学法 荧光原位杂交法 人表皮生长因子受体2 

分 类 号：R737.9[医药卫生—肿瘤]